Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715246 | 1.00 | MAPT (0.56) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL17397643 | 0.94 | MAPT (0.62) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL31276873 | 0.92 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21715270 | 0.91 | MAPT (0.53) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL16762203 | 0.88 | CACNA1B (0.47) | ITGB3ITGA2BPSMB8PSMB9PSMB5 | |
| SCHEMBL29627346 | 0.86 | MAPT (0.53) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21715297 | 0.86 | MAPT (0.53) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL15238747 | 0.86 | CTSK (0.48) | FOLH1 | |
| SCHEMBL28820446 | 0.86 | CTSK (0.48) | FOLH1 | |
| SCHEMBL21543748 | 0.85 | MAPT (0.55) | MAPTKLK7KLK5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | MAPT 3555/4885KLK7 403/4885KLK5 1464/4885 |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | MAPT 4198/4885KLK7 260/4885KLK5 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.